Metrics as of 10/14/2026, 03:53 PM (Berlin time), refresh in progress.
Biofrontera Stock
Biofrontera AG
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- Germany
- CEO
- Hermann Lübbert
- Employees
- 73
- Market cap
- €19 M
- IPO
- 31/10/2006
Biofrontera AG is a biopharmaceutical company operating in the Healthcare sector with a specialization in dermatology. Founded in 1997, the company is headquartered in Leverkusen, Germany. Its business model focuses on the research, development, and commercialization of skin-related products. The primary markets for…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Biofrontera stock: price history
1D
+3.4%
1W
+5.1%
1M
+30.1%
6M
+19.9%
YTD
+25.8%
1Y
+13.3%
2Y
+10.8%
5Y
-93.5%
10Y
-94.4%
Next earnings date
Next earnings date
19/11/2026 (in 33 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Biofrontera
Analyst assessment of Biofrontera
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 19/04/2020
Biofrontera stock metrics
P/E
-1.38
P/B
1.8
EV/EBITDA
-2.79
RETURN ON EQUITY
12.9%
NET MARGIN
59.2%
DEBT/EQUITY
0.11
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
23.0%
FLOAT SHARES
1,397,435
AVG. DAILY VOLUME (30D)
2,826
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Biofrontera stock
What does Biofrontera do?
Biofrontera AG is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Germany.
The CEO is Hermann Lübbert, the company employs around 73 people.
The IPO was on 31/10/2006; the stock trades on XETRA under the ticker B8FK.DE.
What do analysts say about Biofrontera stock?
1 analysts rate the stock, the consensus is Buy (as of 19/04/2020).
This is an external assessment, not a statement by Market Jury.
When does Biofrontera report next?
The next earnings date is 19/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Biofrontera pay a dividend?
No, Biofrontera currently does not pay a dividend.
Which stocks are comparable to Biofrontera?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Merck, Siemens Healthineers, Bayer Aktiengesellschaft and Fresenius.
How can I get Biofrontera stock analyzed?
Clicking "Analyze stock" lets five strategies assess Biofrontera against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.